In adults with postacute sequelae of COVID-19, nirmatrelvir–ritonavir did not improve symptoms at 10 wk
Sign Up to like & getrecommendations! Published in 2024 at "Annals of Internal Medicine"
DOI: 10.7326/annals-24-02172-jc
Abstract: SOURCE CITATION Geng LN, Bonilla H, Hedlin H, et al. Nirmatrelvir-ritonavir and symptoms in adults with postacute sequelae of SARS-CoV-2 infection: the STOP-PASC randomized clinical trial. JAMA Intern Med. 2024;184:1024-1034. 38848477. read more here.
Keywords: adults postacute; nirmatrelvir ritonavir; postacute sequelae; symptoms adults ... See more keywords